Bavarian Nordic
Danish biotechnology company developing, manufacturing, and commercializing vaccines for infectious diseases and other public-health needs.
Last updated August 22, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacture, and commercialization of vaccines. The company is particularly associated with MVA-BN, its proprietary non-replicating viral-vector platform derived from Modified Vaccinia Ankara. MVA-BN is designed to deliver vaccine antigens without replicating in human cells, a characteristic that distinguishes it from some replication-competent vaccinia-based approaches. The platform became the basis for the company's smallpox and mpox vaccine. The product is marketed under different names in different jurisdictions: Imvanex in the European Union, Imvamune in Canada, and Jynneos in the United States. It has been supplied to government stockpiles, including the United States Strategic National Stockpile, and became a major international medical-countermeasure product during the mpox outbreak that began in 2022. The surge in demand also highlighted the importance of advance government procurement, production capacity, and equitable access to scarce vaccines. Some countries and public-health observers raised concerns that pre-existing contracts and national stockpiling could limit access for countries without established procurement arrangements. Bavarian Nordic's work extends beyond orthopoxvirus vaccines. The company has used viral vectors and virus-like particles in its research and development activities and has participated in programs for Ebola and Marburg hemorrhagic fevers, respiratory syncytial virus, cancer-related vaccines, and other infectious diseases. Its Ebola work included collaboration with the United States National Institute of Allergy and Infectious Diseases and Crucell Holland, a Johnson & Johnson company, on a regimen combining Bavarian Nordic's MVA-BN Filovirus technology with an adenoviral-vector technology known as AdVac. The collaboration produced vaccine doses for clinical development during the 2014 West African Ebola crisis, and the regimen was later authorized for medical use in the European Union in 2020. The company has also expanded through acquisitions in travel vaccines. In 2019, it announced an agreement to acquire GSK's Rabipur and RabAvert rabies vaccines and Encepur tick-borne encephalitis vaccine business. In 2023, it announced an agreement to acquire Vivotif for typhoid fever, Vaxchora for cholera, and a late-stage chikungunya vaccine candidate from Emergent BioSolutions. These transactions broadened Bavarian Nordic's commercial portfolio beyond its historically prominent smallpox and mpox franchise. Bavarian Nordic is headquartered in Hellerup, Denmark. Its manufacturing footprint includes facilities in Kvistgård, Denmark, and Thörishaus near Bern, Switzerland. It has research and development facilities in Martinsried, Germany, and offices in the United States, Canada, and France. The company is listed on Nasdaq Copenhagen under the ticker BAVA. In July 2025, it agreed to a proposed acquisition by the private-equity firms Permira and Nordic Capital, reportedly valuing the company at approximately 19 billion Danish kroner. The transaction was terminated in November 2025 after failing to receive sufficient shareholder support. The company therefore remained an independent listed business after the failed transaction.
History
Bavarian Nordic was founded in Denmark in 1994 and developed into a vaccine-focused biotechnology company with activities spanning research, manufacturing, and commercialization. Its scientific identity has been shaped by the use of viral vectors and virus-like particles. The company's best-known platform, MVA-BN, is derived from Modified Vaccinia Ankara. Unlike replication-competent vaccinia approaches, MVA-BN is characterized by an inability to replicate in human cells, which was intended to support a different safety profile for smallpox and related orthopoxvirus vaccination. The MVA-BN platform became the foundation for Bavarian Nordic's principal smallpox and mpox vaccine. Regulatory and commercial names vary by market: Imvanex is used in the European Union, Imvamune in Canada, and Jynneos in the United States. The vaccine was supplied to government stockpiles, including the United States Strategic National Stockpile, reflecting the company's role in the medical-countermeasure sector. During the 2022 mpox outbreak, the product was deployed internationally and demand rose sharply. The response exposed the strategic importance of pre-existing procurement contracts and manufacturing capacity. It also generated concerns about unequal access, vaccine nationalism, and stockpiling by countries that had secured supplies before the outbreak. Bavarian Nordic also pursued filovirus vaccine development. Working with the National Institute of Allergy and Infectious Diseases, the company developed an MVA-BN Filovirus component for Ebola and Marburg disease research. In October 2014, after preclinical work on a combination regimen, Bavarian Nordic joined Crucell Holland, a Johnson & Johnson company, in efforts to develop and manufacture a regimen combining the MVA-BN technology with Crucell/Janssen's adenoviral AdVac technology. The program was connected to the emergency public-health context of the West African Ebola outbreak. By January 2015, Bavarian Nordic had produced an initial 400,000 doses, and clinical testing began in the United Kingdom, with additional studies planned in the United States and Africa. The regimen received authorization for medical use in the European Union in July 2020. The company broadened its commercial base through acquisitions. In 2019, it agreed to acquire GSK's travel-vaccine products Rabipur and RabAvert for rabies and Encepur for tick-borne encephalitis. In 2023, it announced the acquisition of Vivotif for typhoid fever, Vaxchora for cholera, and a late-stage chikungunya candidate from Emergent BioSolutions. These deals added established travel-vaccine brands and late-stage development assets to the MVA-BN-centered business. Bavarian Nordic's operations include headquarters in Hellerup, Denmark; manufacturing sites in Kvistgård, Denmark, and Thörishaus near Bern, Switzerland; research and development facilities in Martinsried, Germany; and offices in the United States, Canada, and France. The company is listed on Nasdaq Copenhagen under BAVA. In July 2025, Permira and Nordic Capital agreed to acquire the company in a transaction reported at about 19 billion Danish kroner. The proposed deal did not obtain sufficient shareholder support and was terminated in November 2025, leaving Bavarian Nordic as an independent listed company. The company's continuing strategic profile combines commercial travel vaccines with government-facing preparedness products and a pipeline based on viral-vector technology.
- 2025
Proposed acquisition is terminated
[1]A proposed acquisition by Permira and Nordic Capital ends after insufficient shareholder support.
- 2023
Emergent travel-vaccine transaction announced
[1]Bavarian Nordic announces the acquisition of Vivotif, Vaxchora, and a late-stage chikungunya candidate from Emergent BioSolutions.
- 2022
MVA-BN deployed during the mpox outbreak
[1]The company's smallpox and mpox vaccine is deployed internationally during the global mpox outbreak.
- 2020
Filovirus vaccine regimen authorized in the European Union
[1]The Ebola-related vaccine regimen developed through the Bavarian Nordic and Johnson & Johnson collaboration receives European Union authorization.
- 2019
GSK travel-vaccine acquisition announced
[1]Bavarian Nordic announces the acquisition of Rabipur or RabAvert and Encepur from GSK.
- 2015
Initial Ebola vaccine doses and clinical testing
[1]Bavarian Nordic produces an initial 400,000 doses of the filovirus vaccine component, and the first clinical trial begins in the United Kingdom.
- 2014
Filovirus collaboration expands
[1]The company joins Crucell Holland and Johnson & Johnson efforts to develop and manufacture a combination vaccine regimen for Ebola-related emergency use.
- 1994
Bavarian Nordic is founded
[1]Bavarian Nordic is established in Denmark as a biotechnology company.
Products and positioning
A specialized vaccine biotechnology company with a strong position in government medical countermeasures, orthopoxvirus vaccines, travel vaccines, and viral-vector research.
Viral-vector vaccine platform
MVA-BN
Bavarian Nordic's proprietary platform is derived from Modified Vaccinia Ankara. It is characterized as non-replicating in human cells and was developed for use in smallpox and mpox vaccination. The platform also supports research programs involving filoviruses and other infectious diseases.
Smallpox and mpox vaccine
Imvanex
The European Union trade name for Bavarian Nordic's MVA-BN smallpox and mpox vaccine. It is based on the company's non-replicating Modified Vaccinia Ankara technology and is used as a medical-countermeasure product.
Smallpox and mpox vaccine
Imvamune
The Canadian market name for the company's MVA-BN vaccine. It is part of Bavarian Nordic's orthopoxvirus vaccine franchise and is intended for smallpox and mpox-related public-health use.
Smallpox and mpox vaccine
Jynneos
The United States trade name for Bavarian Nordic's MVA-BN vaccine. The product has been supplied to the United States Strategic National Stockpile and was deployed during the global mpox response.
Rabies vaccine
Rabipur and RabAvert
Established rabies travel-vaccine brands acquired from GSK as part of Bavarian Nordic's expansion into the travel-vaccine market. The products are associated with rabies prevention for travelers and other indicated populations.
Tick-borne encephalitis vaccine
Encepur
A tick-borne encephalitis vaccine brand acquired from GSK. It expanded Bavarian Nordic's portfolio of established travel and geographically targeted infectious-disease vaccines.
Typhoid vaccine
Vivotif
An oral typhoid vaccine acquired from Emergent BioSolutions in the 2023 transaction. It forms part of Bavarian Nordic's broader portfolio for travel-related infectious-disease prevention.
Cholera vaccine
Vaxchora
A cholera vaccine acquired from Emergent BioSolutions. The product complements Bavarian Nordic's established and acquired travel-vaccine offerings.
Filovirus vaccine candidate
MVA-BN Filovirus
A Bavarian Nordic vaccine component developed for Ebola and Marburg hemorrhagic fever research. It was combined with Johnson & Johnson's adenoviral AdVac technology in a regimen that entered clinical development and was later authorized in the European Union.
Brand decisions
2025
Accept proposed acquisition by Permira and Nordic CapitalM&ABackground
Private-equity firms Permira and Nordic Capital proposed acquiring Bavarian Nordic in a transaction reported at approximately 19 billion Danish kroner.
Action taken
Bavarian Nordic agreed to the proposed acquisition.
Aftermath
The transaction was terminated in November 2025 after insufficient shareholder support, leaving the company listed and independent.
Reported proposed transaction value. 19 billion Danish kroner (July 2025 proposed transaction)
2023
Acquire Emergent travel-vaccine assetsM&ABackground
Bavarian Nordic continued to diversify its commercial vaccine portfolio through acquisition.
Action taken
The company announced an agreement to acquire Vivotif, Vaxchora, and a late-stage chikungunya vaccine candidate from Emergent BioSolutions.
Aftermath
The proposed transaction added typhoid and cholera products and a chikungunya development asset to the company's portfolio.
2019
Acquire GSK travel vaccinesM&ABackground
Bavarian Nordic sought to broaden its commercial vaccine business beyond its orthopoxvirus and development programs.
Action taken
The company announced an agreement to acquire the Rabipur or RabAvert rabies vaccines and Encepur tick-borne encephalitis vaccine business from GSK.
Aftermath
The transaction expanded Bavarian Nordic's travel-vaccine portfolio.
Recent events
Bavarian Nordic announced an agreement to sell its Priority Review Voucher[3]
Reported:
Bavarian Nordic announced an agreement to sell its Priority Review Voucher for USD 95 million. The buyer was not disclosed, and the transaction remained subject to customary closing conditions, including antitrust review.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/bavarian-nordic · Editorial policy · How profiles are compiled